Other Information
−Removed: Table of Content
The exhibits listed below are filed or furnished as part of this report.
Number Description
−Removed: License and Supply Agreement, dated as of September 26, 2022, by and between Aquestive Therapeutics, Inc.
−Removed: and Atnahs Pharma UK Limited (filed herewith).
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a), as amended, under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
11 unchanged sentences
104* Cover Page Interactive Data File (formatted as Inline XBRL document and contained in exhibit 101)
+Added: * Filed herewith.
+ Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the SEC, certain portions of this exhibit have been omitted.
1 unchanged sentence
Table of Content
−Removed: Pursuant to the requirements of the Securities Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the County of Somerset, State of New Jersey.
+Added: Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the County of Somerset, State of New Jersey.
Aquestive Therapeutics, Inc.
−Removed: November 1, 2022 /s/ Daniel Barber
+Added: May 2, 2023 /s/ Daniel Barber
Daniel Barber
1 unchanged sentence
(Principal Executive Officer)
−Removed: November 1, 2022 /s/ A.
+Added: May 2, 2023 /s/ A.
Ernest Toth, Jr.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.